Symbols / BCAB
BCAB Chart
About
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 14.26M |
| Enterprise Value | 9.15M | Income | -64.71M | Sales | — |
| Book/sh | -0.53 | Cash/sh | 0.14 | Dividend Yield | — |
| Payout | 0.00% | Employees | 61 | IPO | — |
| P/E | — | Forward P/E | -0.14 | PEG | — |
| P/S | inf | P/B | -0.36 | P/C | — |
| EV/EBITDA | -0.14 | EV/Sales | — | Quick Ratio | 0.46 |
| Current Ratio | 0.54 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.15 | EPS next Y | -1.34 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -105.09% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 74.26M |
| Shs Float | 47.97M | Short Float | 11.58% | Short Ratio | 2.34 |
| Short Interest | — | 52W High | 1.43 | 52W Low | 0.13 |
| Beta | 1.06 | Avg Volume | 2.37M | Volume | 1.12M |
| Target Price | $10.00 | Recom | None | Prev Close | $0.19 |
| Price | $0.19 | Change | 1.21% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.00
Mean price target
2. Current target
$0.19
Latest analyst target
3. DCF / Fair value
$-7.98
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.19
Low
$10.00
High
$10.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-13 | down | JMP Securities | Market Outperform → Market Perform | — |
| 2025-03-31 | main | Citizens Capital Markets | Market Outperform → Market Outperform | $1 |
| 2025-03-31 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-13 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-09-16 | reit | JMP Securities | Market Outperform → Market Outperform | $5 |
| 2024-05-23 | main | JMP Securities | Market Outperform → Market Outperform | $5 |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-03-28 | reit | JMP Securities | Market Outperform → Market Outperform | $12 |
| 2024-03-27 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-12-05 | reit | JMP Securities | Market Outperform → Market Outperform | $12 |
| 2023-11-08 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-09-25 | main | JP Morgan | Overweight → Overweight | $14 |
| 2023-08-02 | main | JP Morgan | Overweight → Overweight | $17 |
| 2023-08-02 | reit | JMP Securities | Market Outperform → Market Outperform | $12 |
| 2023-08-02 | reit | EF Hutton | Buy → Buy | $25 |
| 2023-08-02 | reit | HC Wainwright & Co. | Buy → Buy | $17 |
| 2023-05-15 | reit | JMP Securities | Outperform → Outperform | $12 |
| 2023-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $17 |
| 2023-05-12 | reit | EF Hutton | Buy → Buy | $25 |
| 2023-04-17 | main | EF Hutton | — → Buy | $25 |
- BioAtla (BCAB) seeks approval for 1-for-50 share conversion and charter changes - Stock Titan Fri, 30 Jan 2026 08
- BioAtla Faces Nasdaq Review of Continued Listing Status - The Globe and Mail ue, 10 Feb 2026 08
- BioAtla stock initiated with Buy rating at Rodman & Renshaw - Investing.com ue, 13 Jan 2026 08
- BioAtla, Inc. Secures $7.5 Million Financing to Support Operations During Strategic Partnership Negotiations - Quiver Quantitative Fri, 21 Nov 2025 08
- BioAtla Creates Super-Voting Share to Advance Reverse Split - TipRanks Mon, 12 Jan 2026 08
- Here's Why We're A Bit Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Situation - simplywall.st Mon, 21 Jul 2025 07
- BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Investing News Network hu, 13 Nov 2025 08
- BioAtla Pursues Share Consolidation Amid Nasdaq Compliance Dispute - The Globe and Mail Sat, 31 Jan 2026 08
- BioAtla Announces Promising Clinical Data for Mec-V in Treatment-Refractory Sarcomas, Demonstrating Median Overall Survival of 21.5 Months | BCAB Stock News - Quiver Quantitative Fri, 07 Nov 2025 08
- BioAtla Sets March Virtual Vote on Internal Merger Plan - TipRanks Wed, 11 Feb 2026 08
- BioAtla stock holds Market Perform rating at JMP as FDA aligns on Phase 3 design - Investing.com ue, 09 Sep 2025 07
- BioAtla (NASDAQ: BCAB) schedules third-quarter call for 4:30 p.m. ET Nov. 13 - Stock Titan Wed, 05 Nov 2025 08
- BioAtla Granted Continued Nasdaq Listing with Conditions - The Globe and Mail ue, 23 Sep 2025 07
- $40M AI-driven cancer deal backs new OPSCC drug into Phase 3 test - Stock Titan Wed, 31 Dec 2025 08
- 45% Cancer Response Rate: BioAtla's Oz-V Drug Gets FDA Green Light for Pivotal Trial in OPSCC - Stock Titan Mon, 08 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 23500 | — | — | Stock Award(Grant) at price 0.00 per share. | STEINMAN LAWRENCE | Director | — | 2025-06-18 00:00:00 | D |
| 1 | 23500 | — | — | Stock Award(Grant) at price 0.00 per share. | MORAN SUSAN | Director | — | 2025-06-18 00:00:00 | D |
| 2 | 23500 | — | — | Stock Award(Grant) at price 0.00 per share. | GRAY MARY ANN | Director | — | 2025-06-18 00:00:00 | D |
| 3 | 23500 | — | — | Stock Award(Grant) at price 0.00 per share. | MCBRINN SYLVIA | Director | — | 2025-06-18 00:00:00 | D |
| 4 | 23500 | — | — | Stock Award(Grant) at price 0.00 per share. | SMITH SCOTT ANDREW | Director | — | 2025-06-18 00:00:00 | D |
| 5 | 23500 | — | — | Stock Award(Grant) at price 0.00 per share. | WILLIAMS EDDIE | Director | — | 2025-06-18 00:00:00 | D |
| 6 | 431000 | — | — | Stock Award(Grant) at price 0.00 per share. | SHORT JAY M | Chief Executive Officer | — | 2025-03-12 00:00:00 | D |
| 7 | 100000 | — | — | Stock Award(Grant) at price 0.00 per share. | WALDRON RICHARD A | Chief Financial Officer | — | 2025-03-11 00:00:00 | D |
| 8 | 85000 | — | — | Stock Award(Grant) at price 0.00 per share. | VASQUEZ CHRISTIAN J | Officer | — | 2025-03-11 00:00:00 | D |
| 9 | 175000 | — | — | Stock Award(Grant) at price 0.00 per share. | SIEVERS ERIC L | Officer | — | 2025-03-11 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -73.83M | -128.47M | -106.94M | -94.76M |
| TotalUnusualItems | 807.00K | 0.00 | 690.00K | |
| TotalUnusualItemsExcludingGoodwill | 807.00K | 0.00 | 690.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -69.78M | -123.46M | -106.48M | -95.40M |
| ReconciledDepreciation | 925.00K | 1.22M | 1.20M | 1.33M |
| EBITDA | -73.02M | -128.47M | -106.94M | -94.07M |
| EBIT | -73.94M | -129.69M | -108.14M | -95.40M |
| NetInterestIncome | 3.37M | 6.31M | 1.65M | 347.00K |
| InterestExpense | 0.00 | 3.00K | ||
| InterestIncome | 3.37M | 6.31M | 1.65M | 350.00K |
| NormalizedIncome | -70.58M | -123.46M | -106.48M | -96.09M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -69.78M | -123.46M | -106.48M | -95.40M |
| TotalExpenses | 84.94M | 129.69M | 108.14M | 96.69M |
| TotalOperatingIncomeAsReported | -73.94M | -129.69M | -108.14M | -96.44M |
| DilutedAverageShares | 58.10M | 47.78M | 47.55M | 34.56M |
| BasicAverageShares | 58.10M | 47.78M | 47.55M | 34.56M |
| DilutedEPS | -1.20 | -2.58 | -2.24 | -2.76 |
| BasicEPS | -1.20 | -2.58 | -2.24 | -2.76 |
| DilutedNIAvailtoComStockholders | -69.78M | -123.46M | -106.48M | -95.40M |
| NetIncomeCommonStockholders | -69.78M | -123.46M | -106.48M | -95.40M |
| NetIncome | -69.78M | -123.46M | -106.48M | -95.40M |
| MinorityInterests | 0.00 | |||
| NetIncomeIncludingNoncontrollingInterests | -69.78M | -123.46M | -106.48M | -95.40M |
| NetIncomeContinuousOperations | -69.78M | -123.46M | -106.48M | -95.40M |
| PretaxIncome | -69.78M | -123.46M | -106.48M | -95.40M |
| OtherIncomeExpense | 798.00K | -87.00K | 10.00K | 691.00K |
| OtherNonOperatingIncomeExpenses | -9.00K | -87.00K | 10.00K | 1.00K |
| SpecialIncomeCharges | 0.00 | 690.00K | ||
| OtherSpecialCharges | -690.00K | |||
| GainOnSaleOfSecurity | 807.00K | |||
| NetNonOperatingInterestIncomeExpense | 3.37M | 6.31M | 1.65M | 347.00K |
| InterestExpenseNonOperating | 0.00 | 3.00K | ||
| InterestIncomeNonOperating | 3.37M | 6.31M | 1.65M | 350.00K |
| OperatingIncome | -73.94M | -129.69M | -108.14M | -96.44M |
| OperatingExpense | 84.94M | 129.69M | 108.14M | 96.69M |
| ResearchAndDevelopment | 63.09M | 103.73M | 79.35M | 58.27M |
| SellingGeneralAndAdministration | 21.85M | 25.96M | 28.79M | 38.42M |
| GeneralAndAdministrativeExpense | 21.85M | 25.96M | 28.79M | 38.42M |
| OtherGandA | 21.85M | 25.96M | 28.79M | 38.42M |
| TotalRevenue | 11.00M | 0.00 | 0.00 | 250.00K |
| OperatingRevenue | 11.00M | 0.00 | 0.00 | 250.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 58.10M | 48.08M | 47.55M | 37.29M |
| ShareIssued | 58.10M | 48.08M | 47.55M | 37.29M |
| TotalDebt | 836.00K | 2.46M | 3.98M | 5.37M |
| TangibleBookValue | 14.27M | 70.67M | 180.34M | 210.82M |
| InvestedCapital | 14.27M | 70.67M | 180.34M | 210.82M |
| WorkingCapital | 36.69M | 88.06M | 197.30M | 227.48M |
| NetTangibleAssets | 14.27M | 70.67M | 180.34M | 210.82M |
| CapitalLeaseObligations | 836.00K | 2.46M | 3.98M | 5.37M |
| CommonStockEquity | 14.27M | 70.67M | 180.34M | 210.82M |
| TotalCapitalization | 14.27M | 70.67M | 180.34M | 210.82M |
| TotalEquityGrossMinorityInterest | 14.27M | 70.67M | 180.34M | 210.82M |
| StockholdersEquity | 14.27M | 70.67M | 180.34M | 210.82M |
| RetainedEarnings | -486.04M | -416.26M | -292.80M | -186.32M |
| AdditionalPaidInCapital | 500.30M | 486.93M | 473.13M | 397.14M |
| CapitalStock | 6.00K | 5.00K | 5.00K | 4.00K |
| CommonStock | 6.00K | 5.00K | 5.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 38.16M | 48.99M | 45.40M | 43.60M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 23.62M | 20.64M | 22.27M | 23.79M |
| OtherNonCurrentLiabilities | 19.81M | 19.81M | 19.81M | 19.81M |
| DerivativeProductLiabilities | 3.81M | 0.00 | ||
| TradeandOtherPayablesNonCurrent | 0.00 | |||
| NonCurrentDeferredLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 836.00K | 2.46M | 3.98M |
| LongTermCapitalLeaseObligation | 0.00 | 836.00K | 2.46M | 3.98M |
| CurrentLiabilities | 14.54M | 28.34M | 23.13M | 19.81M |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 836.00K | 1.62M | 1.52M | 1.39M |
| CurrentCapitalLeaseObligation | 836.00K | 1.62M | 1.52M | 1.39M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.73M | 3.79M | 3.45M | 2.67M |
| PayablesAndAccruedExpenses | 10.98M | 22.93M | 18.16M | 15.75M |
| CurrentAccruedExpenses | 9.08M | 19.11M | 13.93M | 14.57M |
| Payables | 1.90M | 3.82M | 4.23M | 1.18M |
| AccountsPayable | 1.90M | 3.82M | 4.23M | 1.18M |
| TotalAssets | 52.42M | 119.66M | 225.74M | 254.42M |
| TotalNonCurrentAssets | 1.19M | 3.25M | 5.30M | 7.13M |
| OtherNonCurrentAssets | 154.00K | 154.00K | 154.00K | |
| NetPPE | 1.19M | 3.10M | 5.15M | 6.98M |
| AccumulatedDepreciation | -7.00M | -6.08M | -5.36M | -4.26M |
| GrossPPE | 8.19M | 9.18M | 10.52M | 11.23M |
| Leases | 3.68M | 3.68M | 3.69M | 3.69M |
| OtherProperties | 2.79M | 3.77M | 4.69M | 5.42M |
| MachineryFurnitureEquipment | 1.72M | 1.72M | 2.14M | 2.12M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 51.23M | 116.41M | 220.43M | 247.29M |
| OtherCurrentAssets | 447.00K | 320.00K | 539.00K | 502.00K |
| PrepaidAssets | 1.74M | 4.62M | 4.38M | 1.81M |
| CashCashEquivalentsAndShortTermInvestments | 49.05M | 111.47M | 215.51M | 244.98M |
| CashAndCashEquivalents | 49.05M | 111.47M | 215.51M | 244.98M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -71.94M | -104.11M | -90.69M | -63.14M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 9.21M | 0.00 | 61.68M | 70.99M |
| CapitalExpenditure | -98.00K | -268.00K | -924.00K | |
| IncomeTaxPaidSupplementalData | 0.00 | 6.00K | 67.00K | |
| EndCashPosition | 49.05M | 111.47M | 215.51M | 244.98M |
| BeginningCashPosition | 111.47M | 215.51M | 244.98M | 238.60M |
| ChangesInCash | -62.42M | -104.04M | -29.47M | 6.37M |
| FinancingCashFlow | 9.51M | 77.00K | 61.21M | 69.51M |
| CashFlowFromContinuingFinancingActivities | 9.51M | 77.00K | 61.21M | 69.51M |
| NetOtherFinancingCharges | -46.00K | -259.00K | -758.00K | -1.91M |
| ProceedsFromStockOptionExercised | 342.00K | 336.00K | 289.00K | 429.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 9.21M | 0.00 | 61.68M | 70.99M |
| CommonStockIssuance | 9.21M | 0.00 | 61.68M | 70.99M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 0.00 | -98.00K | -265.00K | -924.00K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -98.00K | -265.00K | -924.00K |
| NetPPEPurchaseAndSale | 0.00 | -98.00K | -265.00K | -924.00K |
| SaleOfPPE | 0.00 | 3.00K | 0.00 | |
| PurchaseOfPPE | 0.00 | -98.00K | -268.00K | -924.00K |
| OperatingCashFlow | -71.94M | -104.02M | -90.42M | -62.21M |
| CashFlowFromContinuingOperatingActivities | -71.94M | -104.02M | -90.42M | -62.21M |
| ChangeInWorkingCapital | -11.20M | 4.68M | 287.00K | 7.42M |
| ChangeInOtherWorkingCapital | -641.00K | -593.00K | -513.00K | -331.00K |
| ChangeInPayablesAndAccruedExpense | -13.46M | 5.28M | 3.41M | 7.99M |
| ChangeInPayable | 5.28M | 3.41M | 7.99M | |
| ChangeInAccountPayable | 5.28M | 3.41M | 7.99M | |
| ChangeInPrepaidAssets | 2.90M | -11.00K | -2.61M | -237.00K |
| OtherNonCashItems | 3.00K | |||
| StockBasedCompensation | 8.92M | 13.54M | 14.56M | 25.12M |
| DepreciationAmortizationDepletion | 925.00K | 1.22M | 1.20M | 1.33M |
| DepreciationAndAmortization | 925.00K | 1.22M | 1.20M | 1.33M |
| OperatingGainsLosses | -807.00K | 2.00K | 13.00K | -686.00K |
| GainLossOnInvestmentSecurities | -807.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 2.00K | 13.00K | 4.00K |
| NetIncomeFromContinuingOperations | -69.78M | -123.46M | -106.48M | -95.40M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BCAB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|